• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Podcast: Update on Incretins (Part 1)


Louis Kuritzky, MD, talks about this relatively new treatment option.

Incretins have received a lot of attention as a relatively new treatment option for patients with type 2 diabetes mellitus. What are incretins, and how do they work to regulate blood sugar levels?

Here with a brief update is Louis Kuritzky, MD, Clinical Assistant Professor in the Department of Community Health and Family Medicine at the University of Florida in Gainesville. (Click here for Part 2).

"Take home" Points

1. Incretins are hormones derived from the intestine, not the pancreas. They help to explain why many patients show improvement in diabetes after gastric bypass surgery. The one being most commonly manipulated is called glucagon-like peptide 1 (GLP-1). It increases insulin secretin, suppresses glucagon secretion, and retards emptying of stomach contents into the intestine, as well as affecting satiety.

2. So-called incretin mimetics are drugs that last much longer in the body than GLP-1. The enzyme dipeptidyl peptidase-4 (DPP4) is responsible for its degradation; inhibitors of this enzyme enhance the effects of GLP-1.

For further information on how incretins are used in clinical practice, listen to Part 2.

Update on Incretins (Part 1)


Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
© 2024 MJH Life Sciences

All rights reserved.